Marksans Pharma（MARKSANS）株式概要
マークサンズ・ファーマ・リミテッドは、その子会社とともに、米国、北米、欧州、英国、オーストラリア、ニュージーランド、および国際的な医薬品製剤の研究、製造、マーケティング、販売に従事している。 詳細
MARKSANS Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marksans Pharma Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹259.70 |
| 52週高値 | ₹278.80 |
| 52週安値 | ₹155.00 |
| ベータ | 1.09 |
| 1ヶ月の変化 | 11.37% |
| 3ヶ月変化 | 52.76% |
| 1年変化 | 0.89% |
| 3年間の変化 | 184.29% |
| 5年間の変化 | 195.11% |
| IPOからの変化 | 854.96% |
最新ニュース
ナラティブの更新 • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.
新しいナラティブ • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Recent updates
ナラティブの更新 • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.新しいナラティブ • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
新しいナラティブ • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?分析記事 • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...分析記事 • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...分析記事 • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...分析記事 • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...ナラティブの更新 • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.分析記事 • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...ナラティブの更新 • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.分析記事 • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...分析記事 • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...分析記事 • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...分析記事 • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...分析記事 • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...分析記事 • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...分析記事 • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...分析記事 • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
新しいナラティブ • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.分析記事 • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...分析記事 • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...分析記事 • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...分析記事 • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...分析記事 • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...分析記事 • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...株主還元
| MARKSANS | IN Pharmaceuticals | IN 市場 | |
|---|---|---|---|
| 7D | -1.4% | 3.3% | 1.0% |
| 1Y | 0.9% | 12.6% | -1.4% |
業界別リターン: MARKSANS過去 1 年間で12.6 % の収益を上げたIndian Pharmaceuticals業界を下回りました。
リターン対市場: MARKSANS過去 1 年間で-1.4 % の収益を上げたIndian市場を上回りました。
価格変動
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
安定した株価: MARKSANS 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MARKSANSの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1992 | 1,840 | Mark Saldanha | marksanspharma.com |
マークサンズ・ファーマ社は、その子会社とともに、米国、北米、欧州、英国、オーストラリア、ニュージーランド、および国際的な医薬品製剤の研究、製造、マーケティング、販売に従事している。同社は、疼痛管理、上気道、循環器、中枢神経、抗糖尿病、胃腸、鎮痛、上気道、耳ケア、スキンケア、抗がん、抗潰瘍、抗アレルギー、抗ウイルス、食事療法、心臓、皮膚科、抗ヒスタミン、抗真菌、抗ウイルス、下剤、風邪・咳の治療分野の製品を提供している。また、錠剤やハードゼラチンカプセルなどの固形経口剤、ソフトジェル、エッセンシャルオイル、軟膏、クリームや液剤、処方薬なども製造している。同社はスーパーマーケット、小売店、薬局チェーン、卸売業者に製品を提供している。マークサンズ・ファーマは1992年に設立され、本社はインドのムンバイにある。
Marksans Pharma Limited 基礎のまとめ
| MARKSANS 基礎統計学 | |
|---|---|
| 時価総額 | ₹119.84b |
| 収益（TTM） | ₹4.18b |
| 売上高(TTM) | ₹29.51b |
28.2x
PER（株価収益率4.0x
P/SレシオMARKSANS は割高か？
公正価値と評価分析を参照収益と収入
| MARKSANS 損益計算書（TTM） | |
|---|---|
| 収益 | ₹29.51b |
| 売上原価 | ₹12.77b |
| 売上総利益 | ₹16.74b |
| その他の費用 | ₹12.56b |
| 収益 | ₹4.18b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 9.22 |
| グロス・マージン | 56.72% |
| 純利益率 | 14.16% |
| 有利子負債／自己資本比率 | 1.0% |
MARKSANS の長期的なパフォーマンスは？
過去の実績と比較を見る| Marksans Pharma 配当日 | |
|---|---|
| 配当落ち日 | Aug 20 2026 |
| 配当支払日 | Sep 26 2026 |
| 配当落ちまでの日数 | 44 days |
| 配当支払日までの日数 | 81 days |
MARKSANS 配当は確実ですか？
MARKSANS 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 13:42 |
| 終値 | 2026/07/06 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Marksans Pharma Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |